Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer

PURPOSE: Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed. EXPERIMENTAL DESIGN...

Descripción completa

Detalles Bibliográficos
Autores principales: Belli, Valentina, Sforza, Vincenzo, Cardone, Claudia, Martinelli, Erika, Barra, Giusi, Matrone, Nunzia, Napolitano, Stefania, Morgillo, Floriana, Tuccillo, Concetta, Federico, Alessandro, Dallio, Marcello, Loguercio, Carmelina, Gravina, Antonietta Gerarda, Palma, Raffaele De, Ciardiello, Fortunato, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620258/
https://www.ncbi.nlm.nih.gov/pubmed/28978118
http://dx.doi.org/10.18632/oncotarget.20054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620258/
https://www.ncbi.nlm.nih.gov/pubmed/28978118
http://dx.doi.org/10.18632/oncotarget.20054

Ejemplares similares